Biocon Share Price Rises on 18 August 2026 After USFDA Supplemental Approval for Yesintek Autoinjector
- August 18, 2026
- Posted by: Kunal Singla
- Category: Market
Biocon gets USFDA supplemental approval for Yesintek autoinjectors. Biocon share price at Rs 414.55 (+0.59%). Intraday range Rs 412.15-415.25. Volume 94% below average. 18 August 2026.
Quick Answer
Biocon share price rose 0.59% to Rs 414.55 on 18 August 2026 after its US subsidiary received supplemental USFDA approval for Yesintek (ustekinumab) in 45 mg/0.5 ml and 90 mg/ml single-dose prefilled autoinjector formats. Yesintek was originally approved on November 29, 2024. The supplemental approval expands delivery options, improving market penetration in the US ustekinumab biosimilar space.
Biocon gained 0.59% to Rs 414.55 on 18 August 2026 after its US subsidiary received supplemental USFDA approval for Yesintek (ustekinumab) in 45 mg/0.5 ml and 90 mg/ml single-dose prefilled autoinjector formats. Yesintek was originally approved by the US FDA on November 29, 2024, and this supplemental approval expands delivery options for patients who prefer self-administration via autoinjector over vial-syringe combinations. this metric intraday range was Rs 412.15 to Rs 415.25.
Prefilled autoinjectors are significantly easier for patients to use correctly than vial-syringe preparations, and adding this format to an already-approved biosimilar typically grows market share without a full new drug application process. For the Biocon share price, this is a competitive strengthening event in a market where multiple biosimilars of Stelara (ustekinumab) have been approved. India’s Nifty 50 pharma sector has been a strong performer in the Q1 FY27 earnings season, providing a supportive backdrop for this rate today.
Click Here – Get Free Investment Predictions
Biocon Share Price Key Data: 18 August 2026
| Parameter | Data |
|---|---|
| Biocon Share Price (CMP) | Rs 414.55 |
| Change | +Rs 2.45 (+0.59%) |
| Intraday High | Rs 415.25 |
| Intraday Low | Rs 412.15 |
| Volumes (session) | 10,798 shares vs 5-day avg 186,988 (-94.23%) |
| Catalyst | USFDA supplemental approval: Yesintek autoinjectors |
Biocon share price data as of 18 August 2026. Verify from NSE/BSE.
USFDA Approval Impact on Biocon Share Price
Autoinjector Format Grows Yesintek Market Share
The supplemental USFDA approval for Yesintek autoinjectors directly improves patient convenience. In the US biologic market, physician and patient preference for delivery format is a real factor in prescribing decisions. Adding autoinjector formats gives Biocon’s Yesintek a product attribute that some competitor ustekinumab biosimilars may not yet have, which can drive prescribing shift. This competitive advantage is what this indicator is reacting to today.
Volume Context for this Today
Biocon share price is trading on volumes that are 94% below the recent daily average. This is unusually low volume for a catalyst-driven move. Low-volume price gains are less technically significant than high-volume breakouts: they indicate fewer participants behind the move. Investors tracking the the share price should watch for volume confirmation in the next few sessions before concluding that today’s move signals a new trend rather than a low-conviction reaction to the news.
Track Biocon Share Price and Pharma Sector Research on the Univest Screener
Conclusion
Biocon share price rose 0.59% to Rs 414.55 on 18 August 2026 after the USFDA supplemental approval for Yesintek 45 mg/0.5 ml and 90 mg/ml single-dose prefilled autoinjectors. The the stock gains reflect the competitive strengthening of Yesintek in the US ustekinumab biosimilar market. Monitor the the stock from official NSE and BSE platforms and consult a SEBI-registered financial advisor before making investment decisions.
Download the Univest iOS App or Univest Android App to track Biocon share price live and receive pharmaceutical sector research from Univest.
Disclaimer: Data and figures in this article are sourced from publicly available information and may not always be accurate. Verify all data with NSE (nseindia.com) and BSE (bseindia.com) before investing. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Biocon Share Price
Why is Biocon share price rising today on 18 August 2026?
Ans. the share price is rising on 18 August 2026 because its US subsidiary received supplemental USFDA approval for Yesintek (ustekinumab) in 45 mg/0.5 ml and 90 mg/ml single-dose prefilled autoinjector formats. FDA approvals that expand delivery formats for an already-approved biosimilar increase its market penetration, which is a positive catalyst for the the share price.
What is Yesintek and why does it matter for Biocon share price?
Ans. Yesintek is Biocon’s biosimilar of Stelara (ustekinumab), used to treat plaque psoriasis, psoriatic arthritis, and Crohn’s disease. Originally approved by USFDA on November 29, 2024, the supplemental approval for autoinjector formats improves patient convenience for self-administration. Expanding delivery formats can grow Yesintek’s market share in the competitive US ustekinumab biosimilar space, which is a meaningful driver of this reading.
What is the share price today?
Ans. the share price today on 18 August 2026 is Rs 414.55, up Rs 2.45 or 0.59%. The intraday range for the share price today is Rs 412.15 to Rs 415.25. Volumes stand at 10,798 shares versus the 5-day daily average of 186,988, indicating significantly lower-than-average volume on the session.
What is Biocon’s US biosimilar strategy?
Ans. Biocon operates in the US biosimilar market through Biocon Biologics, which has approved products including Semglee (insulin glargine), Hulio (adalimumab), and Yesintek (ustekinumab). The strategy is to build a portfolio of biosimilars for large-market biologics with expired or expiring patents, and to expand delivery formats (as with the Yesintek autoinjector approval) to grow market penetration. The US biosimilar segment is a key driver of the long-term the share price.
Is Biocon a good investment after USFDA approval?
Ans. The Yesintek autoinjector supplemental approval is a positive development for Biocon, but whether the the share price offers a good entry depends on valuations, the competitive landscape for ustekinumab biosimilars in the US, revenue ramp-up pace, and Biocon Biologics’ overall profitability trajectory. Consult a SEBI-registered financial advisor before investing based on the the share price today.
Why is Biocon share price volume so low today?
Ans. the share price is trading on volumes of 10,798 shares versus a 5-day daily average of 186,988, a 94% reduction. Low volumes on an up-day suggest the the share price gain is driven by a small number of buyers rather than broad institutional accumulation. Momentum investors typically look for high-volume confirmation of share price moves, so the low volume is a signal to watch closely in subsequent sessions before acting on the the share price today gain.
Where can I track Biocon share price live?
Ans. Track the share price live on NSE (nseindia.com) under ticker BIOCON or on BSE (bseindia.com). The Univest app also provides real-time the share price data, analyst research, and price alerts for pharmaceutical stocks.
